A maker of medical devices and software for collecting, processing, and managing blood and plasma, Haemonetics builds the machines and disposable kits used by blood banks, hospitals, and plasma centers — including its NexSys plasma collection systems and apheresis devices that pull out specific components like platelets. The company was founded in 1971 by Dr. Allen "Jack" Latham, Jr., who invented the "Latham Bowl," a transparent disposable centrifuge bowl that automated blood separation. Its name blends "haemo," the Greek word for blood, with "-netics," a nod to genetics and cybernetics.
Haemonetics signs non-exclusive U.S. supply agreement with CSL Plasma for NexSys PCS devices
The agreement has no minimum purchase commitments, and the scope and timing of CSL's transition of plasma collection centers have not been determined.
Show detailsHide details
On August 14, 2026, Haemonetics entered into a non-exclusive supply agreement with CSL Plasma Inc. for NexSys PCS devices with Persona PLUS technology and related disposables in the U.S.
Haemonetics is not updating its fiscal 2027 guidance and expects to discuss the agreement's impact on its November 2026 second fiscal quarter earnings call.
The disclosure was made under Item 7.01 Regulation FD and is not deemed filed for SEC liability purposes.
Haemonetics elects Martin Madaus to its Board of Directors, effective July 24, 2026.
Madaus is a Senior Operating Executive at The Carlyle Group and former CEO of Ortho Clinical Diagnostics and Millipore Corporation.
Show detailsHide details
Martin Madaus was elected as a director of Haemonetics Corporation on July 24, 2026, effective immediately.
He will stand for election at the 2027 annual meeting and is expected to join the Audit and Governance and Compliance Committees.
As a non-employee director, Madaus will receive compensation per the 2026 proxy statement, including an annual equity award of approximately $200,000.
Shareholders at the July 24, 2026 annual meeting approved amendments to the 2019 Long-Term Incentive Plan and the 2007 Employee Stock Purchase Plan.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
Haemonetics announces new two-segment reporting structure effective Q1 FY2027
On June 5, 2026, Haemonetics Corporation issued a press release announcing changes to its reportable segment structure.
Show detailsHide details
The Plasma and Blood Center segments will be combined into a single Apheresis segment, and the Hospital segment will be renamed MedSurg.
The new structure takes effect in the first quarter of fiscal year 2027, which began on March 29, 2026.
The company posted a supplemental presentation with recast historical revenue for fiscal years 2024-2026 and recast FY2027 guidance, but did not reaffirm or update its prior guidance.
The change was disclosed under Item 7.01 Regulation FD and Item 9.01, with the press release attached as Exhibit 99.1.
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits